Cipla Results News Today

The biggest product under manufacture in the Pithampur facility is Advair which has a market size of $700 million

The consolidated revenue from operations Cipla increased more than 14 per cent to Rs 6,589.22 crore in the second quarter of the ongoing fiscal.

Consolidated operating profit, calculated as earnings before interest, taxes, depreciation, and amortization (EBITDA), grew by 31% on year to Rs 1,494.02 crore. Operating margin expanded a sharp 234 basis points to 23.6%.

Cipla Q4: Motilal Oswal expect 12.3% earnings CAGR over FY23-25, led by 9%/11% sales CAGR in DF/NA segments and marginal improvement in profitability.

Cipla Limited, the Indian pharmaceutical major headquartered in Mumbai has reported its earnings for the quarter that ended on 31st March 2023, the Indian pharma giant has registered a rise of 8.3 per cent in its consolidated revenue to be recorded at Rs 5,739 crores in the Quarter Four of Financial Year 2022(Q4FY23) up from Rs 5,260 crores in the corresponding quarter last year, , cipla q4 results, cipla ltd, Quaterly Result, q4 results, pharmaceutical, pharma news, Cipla q4, cipla results, cip...

Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021

The company's EBITDA or earnings before interest, tax, depreciation and amortisation also went up by 4.2 per cent to Rs 1,226.2 crore

The company's revenue from operations grew 10 per cent to Rs 5,520 crore, while EBITDA rose 4 per cent to Rs 1,226 crore.